RxDoctor Payments Data

Michael Brown, MD

Family Medicine · Dillon, SCNPI 1497775670

Payments from drug & device makers

$2,704in general payments, 2019–2025

Across 177 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$806
  • AbbVie$182
  • GSK$178
  • Pfizer$154
  • Amgen$140
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$99
  • plus $1K from 33 others

What the payments were for

  • Food & beverage$2,68899%
  • Other$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,704 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$257,109
Medicare patients
382
Services billed
7,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin296$297,025
EliquisApixaban283$228,624
OzempicSemaglutide211$219,432
TrulicityDulaglutide103$156,153
MounjaroTirzepatide112$134,061
Trelegy ElliptaFluticasone/Umeclidin/Vilanter166$117,468
JanuviaSitagliptin Phosphate69$64,683
XareltoRivaroxaban65$63,666
FarxigaDapagliflozin Propanediol68$60,032
LinzessLinaclotide69$53,133
EntrestoSacubitril/Valsartan55$44,501
RybelsusSemaglutide16$32,260
TradjentaLinagliptin34$24,260
JanumetSitagliptin Phos/Metformin Hcl23$17,203
Lagevrio (Eua)Molnupiravir19$15,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$806$251,692227 claims
PfizerEliquis$154$228,624283 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$178$131,666210 claims
MerckJanuvia, Janumet, Lagevrio (Eua)$16$96,968111 claims
AstraZenecaFarxiga, Symbicort$56$68,57691 claims
Johnson & JohnsonXarelto$41$63,66665 claims
AbbVieLinzess$182$53,13369 claims
NovartisEntresto$75$44,50155 claims
Astellas Pharma US IncMyrbetriq$14$11,20317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Dillon

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →